 The biotech bear market has been particularly hard on Precision Oncology companies - particularly those that came to market on the back of lucrative IPOs. Ideaya IPOd in 2019, raising a modest 55m, and it continues to trade above its IPO price of 10, which is rare. Shares hit a high of 26 last September. 